A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients With Relapsed/Refractory Cancer Indications

Trial Profile

A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients With Relapsed/Refractory Cancer Indications

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 29 Dec 2017

At a glance

  • Drugs Eltanexor (Primary) ; Dexamethasone
  • Indications Colorectal cancer; Multiple myeloma; Myelodysplastic syndromes; Prostate cancer
  • Focus Adverse reactions; First in man
  • Sponsors Karyopharm Therapeutics
  • Most Recent Events

    • 21 Dec 2017 Planned primary completion date changed from 1 Jan 2018 to 1 Jun 2018.
    • 12 Dec 2017 Results (n=36) presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
    • 10 Dec 2017 According to a Kayopharm Therapeutics media release, based on these results, this trial is being expanded to include patients with advanced colorectal cancer (CRC), castration-resistant prostate cancer (crPC), and myelodysplastic syndrome (MDS).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top